Efficacy and Safety of Botulinum Toxin A for Treating Bladder Hyperactivity in Children and Adolescents with Neuropathic Bladder Secondary to Myelomeningocele

<table>Patient number 27: evolution of the patient's urodynamics. (a) Basic urodynamics. (b) Clinical balance and good bladder capacity after the first injection of BTX-A. (c) Eight months after the bladder pressure exceeded 40 cm H<sub>2</sub>O quickly (safety pressure), requiring a new treatment.</table>

Dataset Papers in Science

fig5

Figure 5

Figure 5: Efficacy and Safety of Botulinum Toxin A for Treating Bladder Hyperactivity in Children and Adolescents with Neuropathic Bladder Secondary to Myelomeningocele 

Figure 5 | Efficacy and Safety of Botulinum Toxin A for Treating Bladder Hyperactivity in Children and Adolescents with Neuropathic Bladder Secondary to Myelomeningocele 